NCT05050604View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients

PHASE4UnknownINTERVENTIONAL
Enrollment

418

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Vascular Cognitive Impairment
Interventions
DRUG

Choline Alfoscerate 400mg

Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period

DRUG

Placebo of Choline Alfoscerate 400mg

Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)

UNKNOWN

lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT05050604 - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients | Biotech Hunter | Biotech Hunter